

CTT PHARMACEUTICAL HOLDINGS, INC.

FORM 8-K (Current report filing)

Filed 10/07/26 for the Period Ending 10/02/26

Address	1646 W. SNOW AVE SUITE 138 TAMPA, FL, 33606
Telephone	813-606-0060
CIK	0001035422
Symbol	CTTH
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 2, 2026**

CTT PHARMACEUTICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Florida
(State or Other Jurisdiction
of Incorporation)

333-292497
(Commission
File Number)

90-1253984
(IRS Employer
Identification No.)

1646 W Snow Ave. Suite 138 Tampa, FL 33606
(Address of Principal Executive Offices) (Zip Code)

813-606-0060
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
---------------------	----------------	---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01 Changes in Registrant's Certifying Accountant.

CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has parted ways with its auditor. There were no disagreements to accounting practices. The auditor is simply not handling SEC reporting companies moving forward. CTT Pharma will start looking for a new auditor and will reach out to another auditor the company has worked with before.

Item 9.01 Financial Statements and Exhibits.

(b) Exhibits

Exhibit	Description
16.1	Letter
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTT PHARMACEUTICAL HOLDINGS, INC.
(Registrant)

Date: 10/05/2026

By: /s/ Ryan Khouri
Name: Ryan Khouri
Title: Chief Executive Officer
(Principal Executive, Financial and Accounting Officer)



HOLT PATTERSON
CERTIFIED PUBLIC ACCOUNTANTS
BIG FIRM SERVICES, SMALL FIRM FEES

October 2, 2026

Ryan Khouri, CEO
CTT Pharmaceutical Holdings, Inc.
3853 Northdale Blvd. #268
Tampa, FL 33624

Dear CTT Pharmaceutical Holdings, Inc. Management and Those Charged with Governance:

As of October 2, 2026, Holt & Patterson, LLC hereby resigns as the independent registered public accounting firm of CTT Pharmaceutical Holdings, Inc. We will not be completing an audit of the financial statements for the year ended December 31, 2026.

Pursuant to PCAOB rules and SEC requirements, we will provide a letter to the SEC stating whether we agree with the statements made by CTT Pharmaceutical Holdings, Inc. in its Form 8-K to be filed with the SEC by CTT Pharmaceutical Holdings, Inc. regarding this resignation.

The outstanding professional fees due from CTT Pharmaceutical Holdings, Inc. in connection with the audit of the financial statements for the year ended December 31, 2025 of \$4,825.00 remain due and payable to our firm.

We previously returned to you all original records you provided to us in connection with our previous engagements. Our working paper files, including emails and correspondence, are the property of our firm and will be maintained by us in accordance with our firm's record retention policy.

We will cooperate with any CPA successor firm that you designate to us in writing and will consider any requests for access to or copies of documents in our working paper files in accordance with professional standards. We may require payment in full of all outstanding fees owed to our firm before providing access or copies. You will be charged for our time and expense to comply with any requests for access or copies.

We appreciate the opportunity to have assisted you in the past and wish you a successful future.

Sincerely,

Holt & Patterson, LLC
Chesterfield, MO

260 Chesterfield Industrial Blvd. I Chesterfield, MO 63005 | holtpatterson.com | P 636-530-1040 | F 636-530-1101